PurposeEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have proven
efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

LBA7005 Background: In meta-analyses, platinum-based adjuvant (adj) chemotherapy (CT)
in completely resected NSCLC increased cure rate by∼ 5%. At BR. 19 initiation, adj study …

Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …

Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …

Purpose The development of targeted therapy has introduced new options to improve
treatment outcome in selected patients. The objective of this prospective study was to …